$TMC Alright, listen up. Rough seas ahead. Market makers, hedge funds, anyone with real money will do whatever it takes to shake shares loose. Don’t paper hand your position. We’ve already lost plenty of so called bulls along the way, from under a buck to past $3. I still

$ASTS Deutsche Bank 2024 long term forecast has been spot on January 2025: the stock was in the $20's January 2026: it's pushing $120 Do we climb to $670 next year?

$LAES At this point everyone can clearly see it — my prediction chart played out 100%, not 99%. Go check the chart I posted yesterday and the one from last week. I shared them in advance for one reason only: this is exactly how I trade.

$MAAS just moved from an application-layer operator to a full-stack AI company after acquiring Huazhi Future, completing compute + algorithm + scenario vertical integration. globenewswire.com/NewsRoom/Relea…

$MAAS trades into the open as investors rotate toward vertically integrated AI names like $NVDA $AVGO $SMCI $ASTS $LAC $AMD $MSTR $UNH $IREN $QQQ $BMNR $NAMM $CIFR $INTC $FNMA $ALT $PLTR $BBAI

$MAAS testing resistance at 6.21, volume response will decide follow-through.

$MAAS price update Current: $6.27 Holding gains after expansion = constructive price action.

$MAAS on 1/24 had a wide intraday swing — touched roughly $6.95 intraday high, dipped to about $5.73, and closed back near the mid-range. This is not a one-way breakout or dump, but classic volatility within an ongoing range. The prior day’s up move carried short-term momentum

$UNH its funny.. THE CLOWN runs around telling everyone CREDIT CARDS and Health Insurance are ripping you off.. This Fraud filed for Bankruptcy over 10 times and dodged the draft 6 times. Yeah. Ok. Lol

$MAAS spiked near $7 on the AI acquisition (~$1.1B). Now it’s in a range — not hype, but structural shift from hardware → AI tech. Watch for breakout or support bounce. #StockMarket #Investing

$UNH has a massive FCF expansion setup that the market is underpricing. MCR at 89.1% looks ugly, but it’s cyclical — utilization normalization, better MA pricing, OptumRx leverage, more generics, and tighter fraud/waste controls all push it lower. Every 100 bps MCR improvement =

$ALT Don’t sleep on AstraZeneca. Coadutide P2a (5:1 GLP/glucagon) was… fine, not great — ~10% WL at high dose, missed stat sig on MASH resolution & fibrosis. But AZN is clearly building a MASH team, so I doubt they walk away. Running a long, risky P2b with cota doesn’t feel like

$ASTS a $7 run up would be real nice then a break above $120

$ASTS options flow screams continuation 📈 $120 strike: 13,029 calls vs 1,183 puts (P/C 0.09) — aggressive upside bets. Heavy call stacking $125–$130, while $110–$115 holds as support. Classic gamma ramp setup. Above $120 → $125 → $130 = price discovery.